Primaquine and other 8-amnoquinoline based anti-malarials can cause haemolysis in
subjects with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Correct diagnosis of …

Abstract Background Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most
common enzymopathy worldwide. Primaquine is the only licensed drug that effectively …

Background User-friendly, accurate, point-of-care rapid tests to detect glucose-6-phosphate
dehydrogenase deficiency (G6PDd) are urgently needed at peripheral level to safely …

Development of reliable, easy-to-use, rapid diagnostic tests (RDTs) to detect glucose-6-
phosphate dehydrogenase (G6PD) deficiency at point of care is essential to deploying …

Background Patients infected by Plasmodium vivax or Plasmodium ovale suffer repeated
clinical attacks without primaquine therapy against latent stages in liver. Primaquine causes …

Background Primaquine is essential for the radical cure of vivax malaria, however its broad
application is hindered by the risk of drug-induced haemolysis in individuals with glucose-6 …

Despite the potential benefit of primaquine in reducing Plasmodium falciparum transmission
and radical cure of Plasmodium vivax and Plasmodium ovale infections, concerns over risk …

Background Glucose-6-phosphate-dehydrogenase-deficiency (G6PDd) is a major risk factor
for primaquine-induced haemolysis. There is a need for improved point-of-care and …

Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at risk of
severe haemolysis following the administration of 8-aminoquinoline compounds …

Background The distribution of the enzymopathy glucose-6-phosphate dehydrogenase
(G6PD) deficiency is linked to areas of high malaria endemicity due to its association with …